Published in J Clin Oncol on August 01, 1999
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer (2004) 0.83
Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival. Cancer J (2014) 0.83
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol (2015) 0.83
Progress in treatment of small-cell lung cancer: role of CPT-11. Br J Cancer (2003) 0.83
The Globalization of Cooperative Groups. Semin Oncol (2015) 0.82
Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades. PLoS One (2012) 0.80
Increased dose-intensity in small-cell lung cancer: a failed strategy? J Clin Oncol (1999) 0.80
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. Br J Cancer (2003) 0.79
Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms. J Thorac Oncol (2010) 0.76
Immunotherapy treatments for small-cell lung cancer: past, present and future. Lung Cancer Manag (2015) 0.75
Chemotherapy for small cell lung cancer: a comprehensive review. Oncol Rev (2012) 0.75
Lung cancer. BMJ Clin Evid (2010) 0.75
Lung cancer. BMJ Clin Evid (2009) 0.75
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Current concepts of the immunological function of the thymus. Physiol Rev (1967) 8.37
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
BioJava: an open-source framework for bioinformatics. Bioinformatics (2008) 6.17
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol (2001) 6.07
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med (1999) 5.84
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol (2001) 4.89
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med (2000) 4.54
Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res (1977) 4.02
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol (1999) 3.48
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol (2002) 3.11
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol (2001) 3.06
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol (1991) 3.01
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol (1997) 2.96
Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology (2009) 2.84
Validity of sexual histories in a prospective study of male sexual contacts of men with AIDS or an AIDS-related condition. Am J Epidemiol (1988) 2.81
Anti-lymphocytic antibody--a review. Clin Exp Immunol (1967) 2.75
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73
Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res (2000) 2.65
Asymptomatic Chiari Type I malformations identified on magnetic resonance imaging. J Neurosurg (2000) 2.63
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol (2000) 2.58
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol (1993) 2.56
Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst (1997) 2.52
Kaposi's sarcoma in recipients of renal transplants. Am J Med (1979) 2.45
Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys (1993) 2.42
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
Human monoclonal antibody production. Current status and future prospects. J Immunol Methods (1987) 2.21
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med (1996) 2.15
Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res (1994) 2.11
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 2.10
Dietetic guidelines on food and nutrition in the secondary prevention of cardiovascular disease - evidence from systematic reviews of randomized controlled trials (second update, January 2006). J Hum Nutr Diet (2006) 2.09
Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med (2000) 2.07
Laboratory staff qualifications and accuracy of proficiency test results. A national study. Arch Pathol Lab Med (1992) 2.07
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Risk factors for HIV infection in male sexual contacts of men with AIDS or an AIDS-related condition. Am J Epidemiol (1988) 2.05
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol (2006) 2.04
The natural history of Peyronie's disease. J Urol (1990) 2.02
Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys (1994) 2.01
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1998) 1.91
Effect of antilymphocytic antibody and antibody fragments on human lymphocytes in vitro. Nature (1967) 1.89
Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer (1997) 1.85
The effects of thymus and other lymphoid organs enclosed in millipore diffusion chambers on neonatally thymectomized mice. J Exp Med (1965) 1.78
Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol (2001) 1.77
Psychotic men remanded in custody to Brixton Prison. Br J Psychiatry (1994) 1.77
Second primary malignancies following diagnosis of small-cell lung cancer. J Clin Oncol (1992) 1.77
Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer (2004) 1.76
Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Br Med J (Clin Res Ed) (1983) 1.72
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol (2009) 1.68
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol (1991) 1.67
Cancer incidence among Canadian kidney transplant recipients. Am J Transplant (2007) 1.66
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol (2007) 1.63
The reliability of sexual histories in AIDS-related research: evaluation of an interview-administered questionnaire. Can J Public Health (1987) 1.60
Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res (1996) 1.58
A genomewide suppressor and enhancer analysis of cdc13-1 reveals varied cellular processes influencing telomere capping in Saccharomyces cerevisiae. Genetics (2008) 1.58
Myosin light-chain phosphatase. Biochem J (1976) 1.58
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol (1990) 1.57
Thermography. Its relation to pathologic characteristics, vascularity, proliferation rate, and survival of patients with invasive ductal carcinoma of the breast. Cancer (1996) 1.57
Restriction of the capacity to respond to two antigens by single precursors of antibody-producing cells in culture. J Exp Med (1969) 1.55
Some physical and radiobiological properties of immunologically reactive mouse spleen cells. J Exp Med (1970) 1.55
Quality-of-life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst (1992) 1.55
Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med (1993) 1.55
Estrogen replacement therapy and MRI-demonstrated cerebral infarcts, white matter changes, and brain atrophy in older women: the Cardiovascular Health Study. J Am Geriatr Soc (2000) 1.54
Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res (1997) 1.54
Some factors influencing the ability of anti-lymphocytic antibody to suppress humoral antibody formation. Clin Exp Immunol (1967) 1.52
Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung. J Clin Oncol (1984) 1.51
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol (2002) 1.50
The preparation and properties of anti-lymphocytic sera. Prog Surg (1969) 1.48
[Surgical treatment of the single non traumatic perforation of small bowel: excision-suture or resection-anastomosis]. Ann Chir (2005) 1.45
Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br J Cancer (2006) 1.44
Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Ann Intern Med (1978) 1.44
Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol (2000) 1.43
Structure-property correlations in a combinatorial library of degradable biomaterials. J Biomed Mater Res (1998) 1.42
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol (1989) 1.42
Continuous thoracic epidural analgesia versus combined spinal/thoracic epidural analgesia on pain, pulmonary function and the metabolic response following colonic resection. Acta Anaesthesiol Scand (1996) 1.42
Effect of antilymphocytic antibody and antibody fragments on skin-homograft survival and the blood-lymphocyte count in rats. Lancet (1967) 1.41
Lymphoma of the gastrointestinal tract. Semin Oncol (1999) 1.41
Sexual behaviour changes in a cohort of male sexual contacts of men with HIV disease: a three-year overview. Can J Public Health (1991) 1.40
Effect of anti-rat lymphocyte antibody on humoral antibody formation. Nature (1967) 1.40
Serum uric acid and brain ischemia in normal elderly adults. Neurology (2007) 1.39